EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

PDLIM2 acts as a central regulator of ubiquitination, immune signaling, and mitochondrial metabolism in lung cancer suppression (Review)

Tsung-Hsien Chuang, Jeng-Hung Guo, Jing-Xing Yang, Jen-Chih Tseng, Hung-Jung Wang, Chao-Yang Lai

International Journal of Oncology · 03.07.2026 · 69 (2) · 1-15

DOI: 10.3892/ijo.2026.5909 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Oncology, online erschienen am 03.07.2026. Verfasst von Tsung-Hsien Chuang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 970473, Taiw…. Hauptthemen laut MEDLINE: LIM Domain Proteins, Lung Neoplasms, Mitochondria, Microfilament Proteins. Die Arbeit nennt 162 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer is a leading cause of cancer‑related mortality worldwide, which underscores the need to identify novel targets for improving early detection, therapeutic efficacy, and long‑term patient outcomes. PDZ and LIM domain protein 2 (PDLIM2) is a multifunctional adaptor protein that plays a role in cancer biology, particularly in lung cancer. Although PDLIM2 exerts divergent functions across various cancer types, substantial clinical, genetic, and experimental evidence consistently supports its role as a tumor suppressor in lung cancer. PDLIM2 expression is markedly downregulated in the majority of lung tumors representing various histological subtypes and disease stages, and its loss is strongly associated with poor prognosis. Mechanistically, it functions as an E3 ubiquitin ligase or ubiquitin ligase enhancer to promote the degradation of key transcription factors, including NF‑κB/RelA and STAT3, thereby restraining tumor‑associated inflammation, proliferation, survival, immune evasion, and metabolic reprogramming. PDLIM2 downregulation in lung cancer occurs through coordinated genetic and epigenetic mechanisms, including loss of heterozygosity at chromosome 8p21, promoter hypermethylation, histone deacetylation, and oxidative stress‑driven transcriptional repression. Functionally, the restoration of PDLIM2 suppresses lung tumor growth, enhances chemosensitivity, and promotes antitumor immunity, including response to immune checkpoint inhibitors. In addition, a protumoral mechanism of PDLIM2 downregulation involves mitochondrial dysfunction and accumulation of oncometabolites that lead to the activation of hypoxia inducible factor‑1α signaling. Overall, PDLIM2 is emerging as a biomarker and therapeutic target for lung cancer management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LIM Domain ProteinsLung NeoplasmsMitochondriaMicrofilament ProteinsHumansUbiquitinationGene Expression Regulation, NeoplasticSignal TransductionAnimals

Stichwörter der Autor:innen

PDZ and LIM domain protein 2immunoregulationlung cancermitochondrial metabolismtumor suppressionubiquitination

Substanzen

LIM Domain ProteinsPDLIM2 protein, humanMicrofilament Proteins

Autor:innen und Institutionen

  • Cardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 970473, Taiwan, R.O.C.
  • Department of Neurosurgery, China Medical University Hospital, Taichung 404327, Taiwan, R.O.C.
  • Jim and Eleanor Randall Department of Surgery, Cedars‑Sinai Medical Center, Los Angeles, CA 90048, USA.
  • Immunology Research Center, National Health Research Institutes, Miaoli 350401, Taiwan, R.O.C.
  • Institute of Medical Sciences, Tzu Chi University, Hualien 970374, Taiwan, R.O.C.
  • Department of Medical Laboratory Science and Biotechnology, Asia University, Taichung 41354, Taiwan, R.O.C.

Zitieren

APA

Chuang, T. H., Guo, J. H., Yang, J. X., Tseng, J. C., Wang, H. J., & Lai, C. Y. (2026). PDLIM2 acts as a central regulator of ubiquitination, immune signaling, and mitochondrial metabolism in lung cancer suppression (Review). International Journal of Oncology, 69(2), 1-15. https://doi.org/10.3892/ijo.2026.5909

Vancouver

Chuang TH, Guo JH, Yang JX, Tseng JC, Wang HJ, Lai CY. PDLIM2 acts as a central regulator of ubiquitination, immune signaling, and mitochondrial metabolism in lung cancer suppression (Review). International Journal of Oncology. 2026;69(2):1-15. doi:10.3892/ijo.2026.5909

BibTeX
@article{Chuang2026,
  author = {Chuang, Tsung-Hsien and Guo, Jeng-Hung and Yang, Jing-Xing and Tseng, Jen-Chih and Wang, Hung-Jung and Lai, Chao-Yang},
  title = {PDLIM2 acts as a central regulator of ubiquitination, immune signaling, and mitochondrial metabolism in lung cancer suppression (Review)},
  journal = {International Journal of Oncology},
  year = {2026},
  volume = {69},
  number = {2},
  pages = {1--15},
  doi = {10.3892/ijo.2026.5909}
}
Kostenlos starten →